Brief: Celsion Completes Enrollment Of Phase I/II Ovation 2 Study With Gen-1 In Advanced Ovarian Cancer

Imunon

15/09/2022 13:37

Sept 15 (Reuters) - Celsion Corp  CLSN.O :
    * CELSION COMPLETES ENROLLMENT OF PHASE I/II OVATION 2 STUDY
WITH
GEN-1 IN ADVANCED OVARIAN CANCER
    * CELSION CORP - TOPLINE RESULTS ARE EXPECTED IN SECOND HALF
OF
2023
    * CELSION CORP - PLANS TO REQUEST FDA BREAKTHROUGH THERAPY
DESIGNATION FOR GEN-1 BASED ON ENCOURAGING CLINICAL DATA

Source text for Eikon:  ID:nGNX82JGfv 
Further company coverage:  CLSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))